Gemini Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyenberg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the following investor conferences in November:

Stifel 2020 Virtual Healthcare Conference

Date: Tuesday, November 17

Time: 10:00 AM ET

Jefferies Virtual London Healthcare Conference

Date: Wednesday, November 18

Time: 10:50 AM ET

A live webcast of these events will be available on the "Events & Presentations" page on the Company's website. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

About Gemini Therapeutics

Gemini Therapeutics is a clinical stage precision medicine company developing innovative treatments for age-related macular degeneration (AMD) by developing drugging strategies that are matched to specific genetic mutations found in patients with high clinical unmet need. Gemini’s lead clinical stage candidate, GEM103, is a recombinant form of the naturally occurring complement factor H protein currently in a Phase 2a trial in dry AMD patients with a complement factor H mutation. The company has generated a rich pipeline including recombinant proteins, gene therapies, and monoclonal antibodies. Gemini’s CLARITY natural history study is designed to provide unprecedented insight into the role of genetic risk in common retinal diseases and began in December 2018.

For more information, visit www.geminitherapeutics.com.